LAMA4、FHIT及P16水平变化与肝癌患者病情严重程度的关系

Relationship between changes of LAMA4,FHIT and P16 levels and severity of liver cancer patients

目的:研究层黏连蛋白α4亚基(LAMA4)、脆性组氨酸三联体(FHIT)及P16表达水平与肝癌患者病情严重程度的关系。方法:选取2020年9月至2021年4月在本院进行肝癌手术治疗的120例患者作为研究对象,收集患者术中切除的组织,分为远肝癌组织组(距离肝癌组织≥5 cm)80例,癌旁组织组(距离肝癌组织1~2 cm)80例,肝癌组织组120例,并收集患者术前1 d的空腹肘静脉血,采用qRT-PCR法检测组织中LAMA4、FHIT及P16 mRNA水平,采用ELISA法检测血清中LAMA4、FHIT及P16蛋白水平,Pearson法分析肝癌组织与血清中LAMA4、FHIT、P16的相关性,Spearman法分析LAMA4、FHIT及P16表达与肝癌患者病情严重程度的相关性。结果:肝癌组织组、癌旁组织组、远肝癌组织组中LAMA4 mRNA水平依次降低,FHIT及P16 mRNA水平依次升高,组间两两比较差异有统计学意义(P<0.05)。高分化、中分化、低分化患者血清LAMA4水平依次升高,FHIT及P16水平依次降低,组间两两比较差异有统计学意义(P<0.05)。Ⅰ期、Ⅱ期、Ⅲ期患者血清LAMA4水平依次升高,FHIT及P16水平依次降低,组间两两比较差异有统计学意义(P<0.05)。淋巴结转移患者血清LAMA4高于淋巴结未转移者,FHIT及P16水平低于淋巴结未转移者(P<0.05)。LAMA4、FHIT、P16在肝癌组织中与血清中表达呈正相关(r=0.616、0.517、0.552,均P<0.001)。肝癌患者血清LAMA4水平与分化程度、TNM分期及淋巴结转移均呈正相关(P<0.05),血清FHIT、P16水平均与分化程度、TNM分期及淋巴结转移呈负相关(P<0.05)。结论:肝癌患者组织及血清中LAMA4高表达,FHIT及P16低表达,LAMA4、FHIT及P16水平与肝癌患者分化程度、TNM分期及淋巴结是否转移有关。

Objective:To study the relationship between the expression levels of laminin alpha4(LAMA4),fragile histidine triad(FHIT),P16 and the severity of liver cancer patients.Methods:A total of 120 patients who underwent liver cancer surgery in our hospital from September 2020 to April 2021 were selected as the research objects. The tissues removed during the operation were collected and divided into 80 cases in the liver cancer distant tissue group(distance from liver cancer tissue≥5 cm),80 cases in the adjacent tissue group(1~2 cm from the liver cancer tissue),120 cases in the liver cancer tissue group,and the fasting cubital venous blood was collected from the patient 1 day before the operation,the qRT-PCR method was used to detect the levels of LAMA4,FHIT and P16 mRNAs in the tissues,ELISA method was used to detect the levels of LAMA4,FHIT,P16 proteins in serum,Pearson method was used to analyze the correlation between the expression of LAMA4,FHIT and P16 in liver cancer tissues and serum,Spearman method was used to analyze the correlation between the expression of LAMA4,FHIT and P16 and the severity of liver cancer patients.Results:The level of LAMA4 mRNA in the liver cancer tissue group,adjacent tissue group,and liver cancer distant tissue group decreased sequentially,and the levels of FHIT and P16 mRNA increased sequentially,there was a statistically significant difference between any two groups(P<0.05). The level of serum LAMA4 in well-differentiated,moderately-differentiated,and poorly-differentiated patients increased sequentially,and the levels of FHIT and P16 decreased sequentially,there was a statistically significant difference between any two groups(P<0.05). The level of serum LAMA4 in patients with stageⅠ,ⅡandⅢ increased successively,while the levels of FHIT and P16 decreased successively,there was a statistically significant difference between any two groups(P<0.05). Serum LAMA4 of patients with lymph node metastasis was higher than that of patients without lymph node metastasis,and the levels of FHIT and P16 were lower than those of patients without lymph node metastasis(P<0.05). The expressions of LAMA4,FHIT and P16 in liver cancer tissues were positively correlated with in the serum(r=0.616,0.517,0.552,all P<0.001). The level of serum LAMA4 in patients with liver cancer was positively correlated with the degree of differentiation,TNM staging and lymph node metastasis(P<0.05),the levels of serum FHIT and P16 were negatively correlated with the degree of differentiation,TNM stage and lymph node metastasis(P<0.05).Conclusion:LAMA4 is highly expressed in the tissues and serum of liver cancer patients,while FHIT and P16 are lowly expressed. The levels of LAMA4,FHIT and P16 are related to the differentiation degree,TNM stage and lymph node metastasis of liver cancer patients.